ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to advance Anktiva in non-small cell lung cancer.

Shares of Immunitybio rose 9.81 percent on Thursday to finish at $3.47 apiece as investor sentiment was buoyed by news that ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bisepcifics ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...

Starbucks Corporation SBUX gained 5.7% to $106.15 following better-than-expected quarterly financial results. Additionally, ...

Dubai Science Park the regions leading science-focused ecosystem will contribute to knowledge-building efforts enabling life ...

Dr Matthew McKinney reflects on his first experience of treating DLBCL and highlights the advancements in emerging treatments ...

Dr Matthew McKinney shares advice for new clinicians and investigators, emphasizing mentorship, focus, and skill-building.